INNOVATION1 BIOTECH INC.
INNOVATION1 BIOTECH INC. (GMVP): 4 pipeline candidates · ~1 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
0.7 months
D/E -1.04 · 0% dilution
Lead: Preclinical
4 candidates
N/A
N/A
A transparent, data-derived signal for INNOVATION1 BIOTECH INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$108K
Quarterly Burn
$450K
Runway
0.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| cannabidophorol pro | Preclinical |
| hu-308 pro | Preclinical |
| psilocin pro | Preclinical |
| tetrahydrocannobivarin pro | Preclinical |
Frequently asked questions
How many drug candidates are in INNOVATION1 BIOTECH INC.'s pipeline?
INNOVATION1 BIOTECH INC. (GMVP) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is INNOVATION1 BIOTECH INC.'s lead drug candidate?
INNOVATION1 BIOTECH INC.'s most advanced tracked candidate is cannabidophorol pro (Preclinical) for Refractory pediatric epilepsy.
What is INNOVATION1 BIOTECH INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, INNOVATION1 BIOTECH INC. has approximately 0.7 months of cash runway.
Get the full picture on INNOVATION1 BIOTECH INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.